Skip to main content
. 2017 Feb 19;51(2):103–121. doi: 10.4132/jptm.2017.01.24

Fig. 2.

Fig. 2.

Epidermal growth factor receptor (EGFR)–related signaling pathway in metastatic colorectal cancer. Anti-EGFR antibodies are able to block downstream signal of EGFR in wild type RAS and RAF (left), but unable to block in mutant RAS or RAF (right). mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase.